Baclofen API Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Baclofen USP 

Product Overview

Baclofen is a synthetic pharmaceutical compound belonging to the class of centrally acting skeletal muscle relaxants. It is primarily used in the management of spasticity, a condition characterized by increased muscle tone, stiffness and involuntary muscle contractions. Baclofen is an important active pharmaceutical ingredient (API) used in the development of oral and other approved pharmaceutical formulations.

Baclofen acts mainly on gamma-aminobutyric acid type B (GABA-B) receptors in the central nervous system. By activating these receptors, it helps reduce the release of excitatory neurotransmitters and decreases the excessive nerve signals responsible for increased muscle activity.

It is commonly associated with the management of spasticity resulting from conditions such as multiple sclerosis, spinal cord injuries and other neurological disorders. Its muscle-relaxing activity helps reduce muscle stiffness, spasms and associated discomfort.

Baclofen is also used in pharmaceutical research involving GABA-B receptor activity, neuronal signalling and the development of medicines for conditions associated with abnormal muscle tone.

Chemical Identity and Composition

Baclofen has the molecular formula C₁₀H₁₂ClNO₂, a molecular weight of approximately 213.66 g/mol, and CAS number 1134-47-0.

Chemically, Baclofen is a chlorinated derivative of gamma-aminobutyric acid (GABA). Its structure contains an amino group, a carboxylic acid group and a chlorine-substituted phenyl ring. These structural features contribute to its pharmacological activity and interaction with GABA-B receptors.

Baclofen is also known by the chemical name 4-amino-3-(4-chlorophenyl)butanoic acid. It is a racemic compound containing two enantiomeric forms, although the marketed medicinal substance is generally the racemate unless a specific enantiomer is expressly identified.

Chemical identity details:

  • Product name: Baclofen
  • CAS number: 1134-47-0
  • Molecular formula: C₁₀H₁₂ClNO₂
  • Molecular weight: 213.66 g/mol
  • IUPAC name: 4-amino-3-(4-chlorophenyl)butanoic acid
  • Chemical class: Chlorinated GABA derivative
  • Pharmacological class: Centrally acting skeletal muscle relaxant
  • Primary receptor activity: GABA-B receptor agonist
  • Therapeutic category: Muscle relaxant and antispastic agent

Mechanism of Action

Baclofen acts primarily as an agonist at GABA-B receptors, which are metabotropic receptors found throughout the central nervous system. These receptors play an important role in regulating neuronal excitability and controlling the transmission of nerve signals.

When Baclofen activates GABA-B receptors, it reduces excitatory neurotransmitter release and decreases neuronal activity in pathways involved in muscle reflexes. This helps reduce excessive reflex responses and involuntary muscle contractions.

The general mechanism can be understood through the following steps:

  1. Baclofen reaches the central nervous system after administration.
  2. It binds to and activates GABA-B receptors.
  3. Receptor activation influences intracellular signalling through G-protein-coupled pathways.
  4. Presynaptic calcium entry and neurotransmitter release are reduced.
  5. Postsynaptic potassium conductance may increase, making neurons less excitable.
  6. Excessive excitatory signalling in spinal pathways is reduced.
  7. Muscle tone, spasms and involuntary muscle activity are consequently decreased.

This mechanism makes Baclofen different from muscle relaxants that act primarily through direct effects on skeletal muscle. Its principal action occurs through inhibitory neurotransmission in the central nervous system.

Pharmaceutical Applications

Baclofen is primarily used in pharmaceutical formulations intended for the management of spasticity and certain neurological conditions associated with increased muscle tone.

Spasticity can develop when the normal communication between the brain, spinal cord and muscles is disrupted. It may cause stiffness, painful spasms, restricted movement and difficulties with everyday activities. Baclofen helps manage these symptoms by reducing excessive neuronal activity involved in muscle reflexes.

Its pharmaceutical applications include:

  • Oral tablet formulation development.
  • Oral liquid formulation development, where approved.
  • Management of spasticity associated with multiple sclerosis.
  • Management of spasticity associated with spinal cord injuries and neurological disorders.
  • Pharmaceutical development for muscle stiffness and involuntary muscle spasms.
  • Intrathecal formulation development for selected patients with severe spasticity.
  • Pharmaceutical research involving GABA-B receptor activation.
  • Research into central nervous system signalling and inhibitory neurotransmission.

Baclofen is available in different finished dosage forms depending on the intended route of administration and approved clinical use. Oral tablets and intrathecal formulations are distinct dosage forms with different formulation, manufacturing and quality requirements. Bulk Baclofen API should not be confused with the finished medicinal product.

Product Benefits and Technical Features

  • GABA-B receptor activity: Acts primarily as a GABA-B receptor agonist involved in inhibitory neurotransmission.
  • Muscle-relaxing action: Helps reduce excessive muscle tone and involuntary muscle contractions.
  • Antispastic activity: Used in the management of spasticity associated with neurological conditions.
  • Central nervous system activity: Produces its principal pharmacological effects through neuronal signalling pathways.
  • Defined chemical identity: Has an established CAS number, molecular formula and molecular weight.
  • Multiple formulation applications: Relevant to oral and approved intrathecal pharmaceutical formulations.
  • Established therapeutic use: Recognized in the management of muscle spasticity.
  • Analytical characterization: Can be evaluated using appropriate identification, assay and impurity-testing methods.

Quality and Analytical Considerations

Baclofen intended for pharmaceutical applications should be assessed against an appropriate pharmacopoeial monograph or approved product specification. Quality evaluation should establish the identity, purity, strength and consistency of the API.

Important quality attributes may include:

  • Description and physical appearance.
  • Identification by suitable analytical techniques.
  • Assay or content determination.
  • Related substances and organic impurities.
  • Enantiomeric composition, where required by the applicable specification.
  • Loss on drying or water content, where applicable.
  • Residual solvents, where applicable.
  • Inorganic impurities and residue on ignition, where required.
  • Particle-size distribution, when relevant to the intended formulation.
  • Microbiological quality, where required by the intended dosage form.

Analytical methods such as HPLC may be used for assay and related-substance testing, depending on the applicable pharmacopoeial procedure. Additional techniques may be used to confirm chemical identity and evaluate specific quality attributes.

Because Baclofen contains a stereogenic centre, its stereochemical identity should be considered where the applicable monograph or product specification requires it. The racemic API should not be confused with an individual enantiomer.

The final acceptance criteria should follow the current applicable BP, IP or USP monograph, where available, or an approved specification. Numerical limits should not be assumed from unrelated supplier specifications or research-grade product data.

Why Product Documentation Matters

Product documentation is essential for establishing the identity, quality and traceability of Baclofen API used in pharmaceutical development and manufacturing.

A Certificate of Analysis (COA) provides batch-specific analytical results and demonstrates whether the tested material complies with its stated specification. It should include relevant details such as appearance, identification, assay and related-substance results.

A Safety Data Sheet (SDS) provides information about safe handling, storage, potential hazards, exposure controls and emergency precautions.

Depending on the intended pharmaceutical application and applicable regulatory requirements, supporting documentation may include:

  • Batch-specific Certificate of Analysis.
  • Safety Data Sheet.
  • Approved product specification.
  • Analytical method references.
  • Related-substance and impurity information.
  • Residual-solvent information, where applicable.
  • Stability and storage information.
  • Regulatory and quality declarations, where available.

Documentation should clearly identify the Baclofen chemical form, CAS number, molecular formula, batch number, analytical methods and batch-specific test results.

Key Product Highlights

  • Product: Baclofen
  • CAS Number: 1134-47-0
  • Molecular Formula: C₁₀H₁₂ClNO₂
  • Molecular Weight: 213.66 g/mol
  • Chemical Name: 4-Amino-3-(4-chlorophenyl)butanoic acid
  • Chemical Class: Chlorinated GABA Derivative
  • Pharmacological Class: Centrally Acting Skeletal Muscle Relaxant
  • Primary Receptor Activity: GABA-B Receptor Agonist
  • Product Category: Pharmaceutical API
  • Primary Application: Management of Spasticity
  • Therapeutic Areas: Neurology and Musculoskeletal Care
  • Dosage Forms: Oral and intrathecal formulations, subject to approved product requirements

Frequently Asked Questions

What is Baclofen USP?

Baclofen USP is baclofen intended to meet the applicable United States Pharmacopeia quality requirements.

What is the CAS number of Baclofen?

The CAS Registry Number is 1134-47-0.

What is the molecular formula of Baclofen?

Its molecular formula is C₁₀H₁₂ClNO₂.

What is the molecular weight of Baclofen?

The molecular weight is 213.66 g/mol.

What is the pharmaceutical application of Baclofen?

Baclofen is a centrally acting muscle relaxant and antispastic agent used in medicines for the management of muscle spasticity.

What is the USP assay requirement for Baclofen?

The cited USP monograph specifies 98.0%–102.0% baclofen, calculated on the anhydrous basis. Confirm the currently applicable monograph before publishing this as the product's release specification.

What is the appearance of Baclofen?

Baclofen is described in pharmaceutical product information as a white to off-white or creamy-white powder. Confirm the exact wording against the applicable specification.

Which documents can buyers request?

Buyers can enquire about the applicable COA, SDS, product specification and other relevant technical documents, subject to availability.

How can customers enquire about Baclofen USP API?

Customers can contact Swapnroop Drugs & Pharmaceuticals with their required quantity, grade, destination market and documentation requirements.

Detailed Specifications

Parameter Specification
Appearance White to off-white powder
Identification IR & HPLC compliant
Assay (HPLC) 98.0%–102.0%
Loss on Drying NMT 3.0%
Residue on Ignition NMT 0.3%
Total Impurities NMT 2.0%
Get Bulk Quote via WhatsApp
chatbot/chatbot.js" defer>